Source: Annual Congress 2006 - Novel treatments for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Pascoe, F. Kanniess, J. Bonner, P. Lloyd, P. Lowe, J. Beier, R. Woessner (Horsham, United Kingdom; Grosshansdorf, Wiesbaden, Germany; Basel, Switzerland). A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Eur Respir J 2006; 28: Suppl. 50, 752

Member's Comments

No comment yet.

Related content which might interest you: Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001 Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Reduced late asthmatic response by repeated low-dose allergen exposure Source: Eur Respir J 2001; 17: 872-880 Year: 2001 Induction of allergic bronchial hyperreactivity in DA-rats despite low-level eosinophilia in airways and lack of specific IgE antibodies Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma Year: 2008 Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects Source: Eur Respir J 2007; 30: Suppl. 51, 490s Year: 2007 MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 The effect of smoking on the response to nasal antigen challenge in patients with allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 217s Year: 2002 Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020